THERAPEUTIC TARGETING OF CATHEPSIN C

Transcription

1 ISyCatC International Symposium on Cathepsin C In Honor of Prof. Niels Borregaard THERAPEUTIC TARGETING OF CATHEPSIN C «From Pathophysiology to Treatment» 5 April - 6 April, 2017 TOURS / FRANCE Hôtel Oceania L'Univers Tours Chair: Brice Korkmaz Phone: brice.korkmaz@inserm.fr Scientific committee: Francis Gauthier, Gilles Lalmanach, Adam Lesner (Poland) Sylvain Marchand-Adam, Sandrine Dallet-Choisy

2 The International Symposium ISyCatC will focus on the targeting of cathepsin C, a protease that activates most of tissue-degrading proteases during inflammatory diseases such as COPD, cystic fibrosis, granulomatosis with polyangiitis or rheumatoid arthritis. Cathepsin C thus appears as a potential therapeutic target to impair protease-driven tissue degradation in chronic inflammatory diseases. This symposium will bring together for the first time the world leading specialists from academic labs and industry, working on cathepsin C and its target enzymes. It will associate biochemists studying the functionality of cathepsin C, cell biologists studying its maturation and tissue localization, chemists developing specific cathepsin C inhibitors and clinicians studying the pathologies in which cathepsin C is directly or indirectly involved. With the support of:

3 Le symposium International ISyCatC est consacré à l étude du ciblage de la cathepsine C, une protéase responsable de l activation de la plupart des protéases de dégradation des cellules immunitaires recrutées au cours de pathologies inflammatoires telles que la BPCO, la mucoviscidose, la granulomatose avec polyangéite ou encore la polyarthrite rhumatoïde. La cathepsine C représente donc une cible thérapeutique potentielle pour contrôler la dégradation enzymatique tissulaire qui caractérise les pathologies inflammatoires chroniques. Ce symposium permettra de réunir pour la première fois les principaux spécialistes internationaux des domaines public et privé travaillant sur cette protéase et ses enzymes cibles. Il associera des biochimistes étudiant la fonctionnalité de la protéase, des biologistes cellulaires étudiant sa maturation et sa localisation tissulaire, des chimistes développant des inhibiteurs spécifiques, des cliniciens spécialistes des pathologies dans lesquelles la cathepsine C est directement ou indirectement impliquée. Avec le soutien de:

4 SCIENTIFIC PROGRAMME WEDNESDAY, APRIL 5 Opening lecture Neutrophil serine proteases and their inhibitors: balancing defense and destruction (D. Jenne, Germany) THURSDAY, APRIL 6 SESSION I: Structure and activity of cathepsin C Cysteine cathepsins: oldies but goldies proteases always on the agenda (G. Lalmanach, France) Cathepsin C gene (CTSC): structure and genetic alterations (P. Fergelot, France) Cathepsin C and Papillon-Lefèvre syndrome (C. Moss, UK) SESSION II: Cathepsin C targets and their pathophysiology Neutrophil serine proteases in vasculitis (R. Kettritz, Germany) Characterization of neutrophil disfunction in Papillon-Lefèvre syndrome patients (I. Chapple, UK) Mast cell proteases in asthma (G.H. Caughey, USA) SESSION III: Pharmacological targeting of cathepsin C Cathepsin C substrates and inhibitors (A. Lesner, Poland) Cathepsin C inhibition in mice model of rheumatoid arthritis (J. Pedersen, Denmark) Cathepsin C inhibition in macaque model of lung inflammation (B. Korkmaz, France) Selected Talk Selected Talk Concluding remarks (F. Gauthier / P. Diot, France)

5 Abstract submission deadline is: March 15, 2017 Regular Student, Postdoc Industry Registration fee 50 Euros 30 Euros 150 Euros There is no registration fee for selected talk speakers Venue 5, Boulevard Heurteloup Tours, France 200 metres